Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P435 Real-world clinical outcomes after elective discontinuation of first-use biologics in IBD patients

ECCO'20 Vienna

Year: 2020
Authors:

U.N. Shivaji1, A. Bazarova2, T. Critchlow3, O.M. Nardone4, S.C. Smith4, M. Love3, J. Davis3, S. Ghosh1, M. Iacucci1

1Gastroenterology, NIHR Birmingham Biomedical Research Centre- University Hospitals Birmingham NHS Foundation Trust and University of Birmingham- UK, Birmingham, UK, 2Institute for Biological Physics, University of Cologne, Cologne, Germany, 3Gastroenterology, University Hospitals Birmingham- UK, Birmingham, UK, 4Gastroenterology, Institute of Immunology and Immunotherapy- University of Birmingham, Birmingham, UK

P436 Evaluation of targeted vitamin D supplementation regimen in postoperative patients with Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

Y. LI, L. Zheng, D. Yao, Z. Zhou, B. Liu, Y. Huang, Y. Duan

Department of Surgery, Shanghai Ninth People’s Hospital -Shanghai Jiaotong University School, Shanghai, China

P437 Anti-TNF α antibodies in patients with inflammatory bowel disease naive to anti-TNF therapy treated with biosimilar infliximab (CT-P13): a prospective single-centre real-life study

ECCO'20 Vienna

Year: 2020
Authors:

R. Filip1, A. Pękala1, S. Jarmakiewicz-Czaja2

1Kliniczny Szpital Wojewodzki Nr 2 im. Sw. Krolowej Jadwigi w Rzeszowie, Klinika Gastroenterologii i Centralna Pracownia Endoskopii, Rzeszow, Poland, 2Institute of Health Sciences, Medical College of Rzeszow University, Rzeszow, Poland

P438 Real-life effectiveness and safety of ABP501, an adalimumab biosimilar, in inflammatory bowel disease: a multicentre Italian study

ECCO'20 Vienna

Year: 2020
Authors:

B. Barberio1, F. Zingone1, A. Ferronato2, A. Buda3, P. Melatti1, A. Gubbiotti1, D. Massimi1, C. Casadei1, L. Cingolani4, E.V. Savarino1

1Department of Surgery- Oncology- Gastroenterology, University of Padua, Padua, Italy, 2Pedemontana- Santorso, Digestive Endoscopy Unit, Santorso, Italy, 3Gastroenterology Unit, Feltre Hospital, Santorso, Italy, 4Department of Surgery- Oncology- Gastroenterology, University of Padua, Paduaita, Italy

P439 Patient’ recruitment for a Phase 3 inflammatory bowel disease (IBD) programme is significantly increased when accessing the CT-SCOUT™ platform

ECCO'20 Vienna

Year: 2020
Authors:

Y. Bouhnik1, X. Roblin2, R. Mrad3, X. Hebuterne4, D. Laharie5, C. Tanasa Stefanescu1, S. Nancey6, A. Boureille7, A. Amiot8, N. Sebbah9, L. Peyrin Biroulet10

1Hopital Beaujon, Service de Gastroentérologie- MICI et Assistance Nutritive, Clichy, France, 2Hôpital Bellevue, Service de Gastroentérologie, Saint Etienne, France, 3CTMA, Project Manager, Paris, France, 4Hôpital de l’Archet, Service de Gastroentérologie et Nutrition Clinique, Nice, France, 5Hôpital Haut Lévêque, Service d’Hépato-gastroentérologie, Bordeaux, France, 6Hôpital Lyon Sud, Service d’Hépatogastroentérologie, Lyon, France, 7CHU Hôtel Dieu, Institut des maladies de l’appareil digestif, Nantes, France, 8Hôpital Henri Mondor, Service d’Hépato-Gastro-Entérologie, Creteil, France, 9CTMA, Chief Operating Officer, Paris, France, 10CHU Nancy, Service d’Hépato-gastroentérologie, Nancy, France

P440 Polimedication in patients with inflammatory bowel disease: prevalence and outcomes in a retrospective unicentric series

ECCO'20 Vienna

Year: 2020
Authors:

F. Mesonero Gismero, C. Fernández, E. Sánchez-Rodríguez, A. García-García de Paredes, A. Albillos, A. López-Sanromán

Department of Gastroenterology, Hospital Universitario Ramón y Cajal, Madrid, Spain

P441 Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis

ECCO'20 Vienna

Year: 2020
Authors:

J. Ollech1, I. Normatov2, S. Dwadasi2, S. Dalal2, D. Micic2, A. Israel2, J. Labas2, P. Joel2, R. Cohen2, D. Rubin2, S. Atsushi2

1Gastroenterology, Rabin Medical Center- University of Chicago Medicine, Petach Tikva, Israel, 2Gastroenterology, University of Chicago Medicine, Chicago, USA

P442 Long-term quality of life after surgery for perianal Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

I. Angriman, M. Tomassi, G. Bordignon, R. Bardini, C. Ruffolo, M. Scarpa

Department of Surgical and Gastroenterological Sciences, University of Padova, Padova, Italy

P443 Magnetic resonance imaging after ligation of the intersphincteric fistula tract for high perianal fistulas in Crohn’s disease: a retrospective cohort study

ECCO'20 Vienna

Year: 2020
Authors:

E. Van Praag1, K. van Rijn2, M. Monraats2, J. Stoker2, C. Buskens1

1Amsterdam UMC, Surgery, Vleuten, The Netherlands, 2Amsterdam UMC, Radiology and Nuclear Medicine, Amsterdam, The Netherlands

P444 The impact of azathioprine on inflammatory bowel disease patients’ overall health-related quality of life: a single-centre retrospective cohort study

ECCO'20 Vienna

Year: 2020
Authors:

Y. ALRUTHIA1, W. Alsharif1, G. Almuaythir1, H. Alrasheed1, O. Alharbi2, N. Azzam2, M. Almadi2, M. Saeed2, B. HajkhderMullaissa2, A. Aljebreen2

1Clinical Pharmacy, King Saud University College of Pharmacy, Riyadh, Saudi Arabia, 2Gastroenterology Division- Department of Medicine, King Khalid University Hospital, Riyadh, Saudi Arabia

P445 Efficacy and safety of induction therapy with calcineurin inhibitors followed by maintenance therapy with vedolizumab in severe ulcerative colitis: a large patient cohort with long-term follow-up

ECCO'20 Vienna

Year: 2020
Authors:

J. OLLECH1, S. Dwadasi1, I. Normatov1, A. Israel1, V. Rai1, P. Sossenheimer1, B. Christensen2, S. Dalal1, J. Pekow1, A. Sakuraba1, R. Cohen1, D. Rubin1

1Gastroenterology, University of Chicago Medicine, Chicago, USA, 2Gastroenterology, The Royal Melbourne Hospital, Melbourne, Australia

P446 Transcriptional and microbial biomarkers of response to anti-TL1A therapy in ulcerative colitis: the Phase 2a TUSCANY study

ECCO'20 Vienna

Year: 2020
Authors:

M. Hassan-Zahraee1, Z. Ye1, L. Xi1, M.L. Baniecki1, X. Li1, W. Farin2, L. Tibaldi3, J.R. Allegretti4, J. Romatowski5, E.J. Scherl6, M. Klopocka7, C. Hyde1, S. Danese8, R. Longman6, K.E. Hung1

1Pfizer Inc., Cambridge, Massachusetts, USA, 2Enterome, Data Science Department, Paris, France, 3Enterome, Drug Discovery Department, Paris, France, 4Brigham and Women’s Hospital- Harvard Medical School, Division of Gastroenterology- Boston, Massachusetts, USA, 5J. Sniadecki’s Regional Hospital, Internal Medicine and Gastroenterology Department, Białystok, Poland, 6Jill Roberts Center for IBD- Weill Cornell Medicine, Division of Gastroenterology and Hepatology- New York, New York, USA, 7Department of Gastroenterology and Nutrition, Nicolaus Copernicus University in Toruń- Collegium Medicum, Bydgoszcz, Poland, 8Department of Gastroenterology, IBD Center- Humanitas Research Hospital, Milan, Italy

P447 No severe neonatal and maternal complications in inflammatory bowel diseases patients treated with ustekinumab or vedolizumab during pregnancy

ECCO'20 Vienna

Year: 2020
Authors:

P. Wils1, P. Seksik2, C. Stefanescu3, S. Nancey4, M. Allez5, D. Laharie6, G. Pineton De Chambrun7, R. Altwegg7, C. Gilletta8, L. Vuitton9, S. Viennot10, M. Serrero11, M. Fumery12, G. Savoye13, M. Collins14, F. Goutorbe15, H. Brixi16, G. Bouguen17, N. Tavernier18, M. Boualit19, A. Amiot20, V. Abitbol21, B. Pariente22

1GETAID group, 1Gastroenterology Department, CHRU Lille, Lille, France, 2Gastroenterology, Saint Antoine Hospital, Paris, France, 3Gastroenterology, Beaujon Hospital, Paris, France, 4Gastroenterology, Lyon Sud Hospital, Lyon, France, 5Gastroenterology, Saint Louis Hospital, Paris, France, 6Gastroenterology, Haut-Leveque Hospital, Bordeaux, France, 7Montpellier, Gastroenterology, Montpellier, France, 8Toulouse, Gastroenterology, Toulouse, France, 9Besancon, Gastroenterology, Besancon, France, 10Caen Hospital, Gastroenterology, Caen, France, 11North Hospital of Marseille, Gastroenterology, Marseille, France, 12CHU Amiens Nord, Gastroenterology, Amiens, France, 13Rouen, Gastroenterology, Rouen, France, 14Kremlin-Bicêtre Hospital, Gastroenterology, Paris, France, 15Bayonne, Gastroenterology, Bayonne, France, 16Robert Debré University Hospital, Gastroenterology, Reims, France, 17University Hospital of Rennes, Gatsroenterology, Rennes, France, 18Gastroenterology, Tourcoing, Tourcoing, France, 19Gastroenterology, Valenciennes, Valenciennes, France, 20Gastroenterology, Henri Mondor Hospital, Paris, France, 21Gastroenterology, Cochin Hospital, Paris, France, 22Gastroenterology, University of Lille- CHRU Lille, Lille, France

P448 Dose adjustment in patients with moderate-to-severe ulcerative colitis: results from the UNIFI maintenance study long-term extension

ECCO'20 Vienna

Year: 2020
Authors:

S. Danese1, R. Panaccione2, L. Peyrin-Biroulet3, C. Marano4, C.D. O’Brien4, H. Zhang5, Y. Zhou5, J. Johanns5, E. Scherl6, R.W.L. Leong7, D.S. Rowbotham8, R.P. Arasaradnam9, B.E. Sands10

1UNIFI Investigators, 1Humanitas Research Hospital, Inflammatory Bowel Diseases Center, Milan, Italy, 2Department of Medicine, University of Calgary, Calgary, Canada, 3Gastroenterology, Nancy University Hospital, Nancy, France, 4Janssen Research and Development- LLC, Immunology, Spring House, USA, 5Janssen Research and Development- LLC, Clinical Biostats, Spring House, USA, 6Weill Cornell Medicine, Jill Roberts Center for Inflammatory Bowel Disease, New York, USA, 7Gastroenterology, Concord and Macquarie University Hospitals, Sydney, Australia, 8Gastroenterology and Hepatology, Auckland City Hospital, Auckland, New Zealand, 9Gastroenterology, University Hospital Coventry and Warwickshire NHS Trust, Coventry, UK, 10Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, USA

P449 Systematic review with meta-analysis: risk of lymphoma associated with anti-tumour necrosis factor (TNF) agents in inflammatory bowel disease

ECCO'20 Vienna

Year: 2020
Authors:

A. CHUPIN1, V. Perduca2, C. Bellanger1, F. Carbonnel1, C. Dong1

1Gastroenterology Department, Kremlin Bicetre Hospital- AP-HP- University Paris Sud, Paris, France, 22 MAP5 laboratory UMR CNRS 8145, Paris Descartes University, Paris, France

P450 Thioguanine and low dose thiopurines and allopurinol are both safe options after failure of conventional thiopurines: a comparative analysis of two multicentre cohorts

ECCO'20 Vienna

Year: 2020
Authors:

V. Biemans Drs1, E. Savelkoul2, G. Dijkstra3, M. Simsek4, R. Gabriels5, M. Pierik6, R. West7, N. de Boer8, F. Hoentjen2

1Gastroenterology and Hepatology, Radboud University Nijmegen Medical Centre- Maastricht University Medical Centre, Nijmegen, The Netherlands, 2Gastroenterology and Hepatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, 3Gastroenterology and Hepatology, University Medical Centre Groningen- Groningen University, Groningen, The Netherlands, 4Gastroenterology and Hepatology, Amsterdam University Medical Centre- Vrije Universiteit, Amsterdam, The Netherlands, 5Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands, 6Gastroenterology and Hepatology, Maastricht University Medical Centre, Maastricht, The Netherlands, 7Gastroenterology and Hepatology, Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands, 8Gastroenterology and Hepatology, Amsterdam University Medical Centre- Vrije Universiteit- Amsterdam Gastroenterology and Metabolism Research Institute, Amsterdam, The Netherlands

P451 Short-and long-term effectiveness of ustekinumab in patients with Crohn’s disease: real-world data from a German IBD cohort

ECCO'20 Vienna

Year: 2020
Authors:

A. Kubesch1, L. Rueter1, K. Farrag2, T. Krause3, K. Stienecker4, J. Hausmann1, N. Filmann5, A. Dignass6, J. Stein2, I. Blumenstein1

1Department of Internal Medicine 1, University Hospital Frankfurt, Frankfurt a. M., Germany, 2Crohn- und Colitis Zentrum, Rhein-Main, Frankfurt a. M., Germany, 3R. Rautenkranz- T. Krause, Gastroenterologie Opernstraße- CED-Schwerpunktpraxis, Kassel, Germany, 4Dr. Stienecker, CED Schwerpunktpraxis, Fulda, Germany, 5Institute of Biostatistics and Mathematical Modeling, University Hospital Frankfurt, Frankfurt a. M, Germany, 6Department of Internal Medicine I, Agaplesion Markus Krankenhaus, Frankfurt a. M., Germany

P452 Biologic use patterns and predictors for non-persistence and switching of biologics in patients with inflammatory bowel disease: a nationwide population-based study

ECCO'20 Vienna

Year: 2020
Authors:

Y.S. Jung Prof. Dr.1, M. Han2, S. Park3, J.H. Cheon4

1Department of Internal Medicine, Kangbuk Samsung Hospital, Seoul, Republic of Korea, 2Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea, 3Department of Biostatistics, Yonsei University, Seoul, Republic of Korea, 4Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea

P453 Comparison of therapeutic effects between groups of thiopurine alone and combination of thiopurine with 5-ASA after remission introduced by oral tacrolimus for patients with severe ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

T. Sato1, K. Kojima2, R. Koshiba2, K. Fujimoto2, M. Kawai2, K. Kamikoduru2, Y. Yokoyama2, T. Miyazaki2, K. Watanabe1, N. Hida2, S. Nakamura2

1Department of Intestinal Inflammation Research, Hyogo College of Medicine, Nishinomiya, Japan, 2Department of Inflammatory Bowel Disease- Division of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan

P454 Serum oncostatin M predicts mucosal healing in Crohn’s disease patients treated with infliximab

ECCO'20 Vienna

Year: 2020
Authors:

L. Bertani1, L. Antonioli2, M. Fornili2, M. Fornai2, G. Tapete1, E. Albano1, G. Baiano Svizzero1, L. Ceccarelli3, M.G. Mumolo3, L. Baglietto2, S. Marchi1, C. Blandizzi2, F. Costa3

1Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, 2Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 3Department of General Surgery and Gastroenterology - IBD Unit, Pisa University Hospital, Pisa, Italy